Navigation Links
Emerging Data From Upsher-Smith's CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Date:3/11/2013

MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013.

Upsher-Smith's CNS pipeline consists of two Phase III programs: USL255 (topiramate), an investigational extended-release topiramate for the management of epilepsy in adults; and USL261 (midazolam) for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters.  Additionally, USL260 (tonabersat) is a potential first-in-class neuronal gap junction modulator in Phase I of development for treatment of epilepsy.

"Upsher-Smith is committed to improving the lives of people living with epilepsy by developing innovative treatments to address the unmet needs of those who suffer from this condition," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "We are very pleased with the progress that has been made with each of our investigational CNS drug programs and are excited to share our ongoing scientific research in epilepsy at AAN's Annual Meeting."

Upsher-Smith sponsored posters include:

  • Single, High Doses of USL255, an Extended-Release Topiramate Formulation, Are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects
  • Poster 04.212; Session P04: Epilepsy: Antiepileptic Medications: Special Populations and Pharmacokinetics; Wednesday, March 20, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration
  • P02.211; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam
  • Poster 02.212; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy
  • Poster 02.209; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m. To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.  

    About Epilepsy
    Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1

    About Upsher-Smith
    Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals.  Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology and women's health.  In addition to products currently marketed, Upsher-Smith has an emerging neurology pipeline with three products in clinical development, two of which are in Phase III clinical trials.  For more information, visit www.upsher-smith.com.

    References
    1. Epilepsy Foundation. About Epilepsy. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm.  Accessed February 4, 2013.


    '/>"/>
    SOURCE Upsher-Smith Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
    2. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
    3. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
    4. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
    5. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
    6. Cumberland Emerging Technologies Expands Life Sciences Center
    7. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
    8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
    9. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
    10. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
    11. Cepheid Announces Executive Vice President Emerging Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
    (Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
    (Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
    (Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
    Breaking Medicine News(10 mins):